Business Wire

Mike Parrish Appointed as CEO, Howden U.S. and Jim Hays as Vice Chairman, Howden Group Holdings

4.8.2025 18:42:00 CEST | Business Wire | Press Release

Share

Howden, the global insurance intermediary group, today announces the appointment of Mike Parrish as Chief Executive Officer, Howden U.S., and of Jim Hays as Vice Chairman, Howden Group Holdings. Mike will build a next-generation U.S. retail broking business for clients and talent, bringing Howden’s unique employee-ownership driven and client-centric model to the largest and most dynamic insurance market in the world. Jim will bring more than 40 years’ U.S. insurance industry experience to the Howden Group Board.

Mike is one of the industry’s most successful business builders, with a proven track record of scaling highly successful U.S. operations. His appointment reflects Howden’s approach to empowering the very best leaders in each territory to build great businesses by attracting exceptional talent and giving that talent the freedom to put their clients at the heart of the business. Mike spent the best part of two decades at Aon, where he built a market-leading business, before joining Marsh in 2021. He will join Howden in September, subject to the fulfilment of relevant contractual obligations.

Jim is a deeply experienced U.S. insurance executive and entrepreneur who previously served as Chief Executive Officer of Hays Company, an insurance broker which he founded in 1994 and sold to Brown & Brown in 2018. He served as Vice Chair and as a member of the Board of Brown & Brown, Inc. He started Hays as a seven-person operation and oversaw more than 25 years of growth to build one of the leading independent U.S. brokers.

Howden started with three people in 1994 and has become a top 10 global broker with more than 22,000 people, including nearly 6,000 employee shareholders who own 34% of the Group. It has done this by attracting entrepreneurs to build businesses across 56 countries, today managing $47 billion in premiums and providing a full-service offering across retail, specialty, and reinsurance broking, risk capital advisory, employee benefits, and underwriting and program management.

Howden already has substantial operations in the U.S. where more than a quarter of its revenue is generated. It has operated in the U.S. for more than a decade through DUAL, one of the world’s largest Managing General Agents, through Howden Re, one of only four global reinsurance brokers, and through many years of supporting US-domiciled clients as their wholesale broker in international markets, with more than $18bn of US premiums today.

Jim Hays, Vice Chairman, Howden Group Holdings,said: “I could not be more energized to join this incredibly exciting, deeply ambitious Group with its army of entrepreneurs dedicated to serving clients. And of course, to work with David, who is in my view one of the most visionary leaders in business today. I was privileged to count Neil Armstrong as a personal friend, so the fact that the news of Howden’s further investment in the USA was first rumoured in the press on the 21st July - the day an American first walked on the Moon – was particularly apposite for me.”

David Howden, CEO, Howden,said: “From the beginning we built Howden on the principle that if we look after our people they will look after our clients. This means we hire great people and get out of their way, truly empowering them to do what’s best for their clients. This is why our organic growth consistently outperforms the market.

“Mike’s appointment is an incredibly important moment in our 30-year history of building a global group with an energetic and entrepreneurial culture, owned by the people who work in it. The foundation of our success has always been in finding the right leaders who are driven to build a business they can be proud of. In Mike we’ve found one of insurance’s most outstanding leaders, with an owner’s mindset and an unrivalled track-record, who wants the freedom to build a business that is an alternative home for talent and clients in the U.S. And in Jim we have one of the most accomplished entrepreneurs in the U.S., who brings a wealth of experience to the Group Board as we accelerate towards our ambitious 2030 vision.

“I am passionate about the role insurance can play in the world, facilitating growth and helping to solve some of the biggest challenges we are facing. In a consolidating market we’re answering a clear desire from clients, insurers, and talent for choice by being the destination for top talent. And I am especially proud that when others in the broking market are cutting costs, we are investing to create jobs in the U.S. to provide better service to clients. We will combine the full weight of our global capabilities to deliver expertise and service with a difference in the U.S. and internationally.

“Our doors are now open. We can’t wait to get started.”

About Howden

Howden is a global insurance intermediary group with employee ownership at its heart. Founded in 1994, it provides insurance broking, reinsurance broking and underwriting services and solutions to clients ranging from individuals to the largest multinational companies.

The group operates in 56 countries across Europe, Africa, Asia, the Middle East, Latin America, the USA, Australia and New Zealand, employing 22,000 people and handling $47bn of premium on behalf of clients.

Further information can be found at www.howdengroup.com and www.howdengroupholdings.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250804162079/en/

Contacts

Howden
pressenquiries@howdengrp.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye